Recently, an investor inquired on an investor platform about the nicotine purity of Rundu Corporation (002923), the company's compliance with medical standards, as well as their nicotine production and primary customer base.
Rundu International responds to investors: Currently, Rundu International offers customized production based on customer needs, providing different purity levels of nicotine for various sectors including pharmaceuticals, pesticides, e-cigarettes, lozenges, and nicotine patches. The designed production capacity for the company's alkaloid (nicotine) project is 100 tons/year for plant extraction and purification processes, and 400 tons/year for chemical synthesis processes of alkaloids and intermediate products. The existing capacity is sufficient to meet sales demands. The company is actively exploring markets and adjusting production plans in a timely manner in accordance with local market access mechanisms.
We welcome news tips, article submissions, interview requests, or comments on this piece.
Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn
Notice
1. This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.
2. The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.
3. This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.
4. Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.
Copyright
This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.
For copyright-related inquiries, please contact: info@2firsts.com
AI Assistance Disclaimer
This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.
We welcome any corrections or feedback. Please contact us at: info@2firsts.com
